Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

945 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report.
Shankar A, Hall GW, Gorde-Grosjean S, Hasenclever D, Leblanc T, Hayward J, Lambilliotte A, Daw S, Perel Y, McCarthy K, Lejars O, Coulomb A, Oberlin WO, Wallace WH, Landman-Parker J. Shankar A, et al. Among authors: hayward j. Eur J Cancer. 2012 Jul;48(11):1700-6. doi: 10.1016/j.ejca.2011.10.018. Epub 2011 Nov 15. Eur J Cancer. 2012. PMID: 22093944
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.
Shankar AG, Roques G, Kirkwood AA, Lambilliotte A, Freund K, Leblanc T, Hayward J, Abbou S, Ramsay AD, Schmitt C, Gorde-Grosjean S, Pacquement H, Haouy S, Boudjemaa S, Aladjidi N, Hall GW, Landman-Parker J. Shankar AG, et al. Among authors: hayward j. Br J Haematol. 2017 Apr;177(1):106-115. doi: 10.1111/bjh.14518. Epub 2017 Feb 21. Br J Haematol. 2017. PMID: 28220934 Free article.
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response.
Sereda S, Shankar A, Weber L, Ramsay AD, Hall GW, Hayward J, Wallace WHB, Landman-Parker J, Braeuninger A, Hasenclever D, Schneider A, Mauz-Koerholz C, Koerholz D, Gattenloehner S. Sereda S, et al. Among authors: hayward j. Blood Adv. 2023 Oct 24;7(20):6285-6289. doi: 10.1182/bloodadvances.2023010652. Blood Adv. 2023. PMID: 37611165 Free PMC article.
Opportunities for targeted therapies: trametinib as a therapeutic approach to canine oral squamous cell carcinomas.
Peralta S, Katt W, Balkman C, Butler S, Carney P, Todd-Donato A, Drozd M, Duhamel G, Fiani N, Ford J, Grenier J, Hayward J, Heikinheimo K, Hume K, Moore E, Puri R, Sylvester S, Warshaw S, Webb S, White A, Wright A, Cerione R. Peralta S, et al. Among authors: hayward j. Res Sq [Preprint]. 2024 May 2:rs.3.rs-4289451. doi: 10.21203/rs.3.rs-4289451/v1. Res Sq. 2024. PMID: 38746473 Free PMC article. Preprint.
945 results